IOncology

At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.

Editor’s Note: With its remarkable therapeutic efficacy, DS-8201 has dramatically reshaped the treatment landscape for patients with advanced breast cancer. In HER2-positive advanced breast cancer, DS-8201 has firmly established its…

Editor's Note: Bladder cancer is one of the common malignant tumors among residents in China, with 75% of bladder cancers being non-muscle-invasive bladder cancer (NMIBC) with a high postoperative recurrence…

Editor’s Note: Endocrine therapy remains one of the standard adjuvant treatments for patients with hormone receptor-positive, HER2-negative (HR+/HER2−) early-stage breast cancer. In recent years, research in this field has made…

Editor’s Note: Anti-HER2 therapy has long been the cornerstone of treatment for patients with HER2-high (IHC 3+ or IHC 2+/FISH+) advanced gastric cancer. In recent years, combining anti-HER2 therapy with…

Editor’s Note: Over the past two decades, clinical research on breast cancer in China has achieved a remarkable transformation — from “following” international standards to “running alongside”, and even “leading”…

Editor’s Note:  On May 29, 2025, the originator, next-generation CDK4/6 inhibitor Lerociclib received approval from China’s National Medical Products Administration (NMPA) for both first-line and second-line indications in HR+/HER2– advanced…

Editor’s Note: As a standard treatment for hormone receptor–positive, HER2–negative metastatic breast cancer (HR+/HER2- MBC), CDK4/6 inhibitors (CDK4/6i) have significantly improved therapeutic outcomes and expanded treatment options. However, developing next-generation…

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) have become an important therapeutic option for hormone receptor–positive, HER2–negative (HR+/HER2-) breast cancer, yet there remains room for improvement in efficacy and safety.  Recently, the…